Evidence map›Paper›PMID 37181773›Full record

ArticleChemical science2023

Facile access to chiral γ-butyrolactones

Yuxuan Zhou, Siyuan Guo, Qiyuan Huang, Qiwei Lang, Gen-Qiang Chen, Xumu Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuxuan ZhouShenzhen Grubbs Institute, Department of Chemistry, and Medi-Pingshan, Southern University of Science and Technology Shenzhen 518000 People's Republic of China langqw@sustech.edu.cn chengq@sustech.edu.cn zhangxm@sustech.edu.cn.
Siyuan GuoShenzhen Grubbs Institute, Department of Chemistry, and Medi-Pingshan, Southern University of Science and Technology Shenzhen 518000 People's Republic of China langqw@sustech.edu.cn chengq@sustech.edu.cn zhangxm@sustech.edu.cn.
Qiyuan HuangShenzhen Grubbs Institute, Department of Chemistry, and Medi-Pingshan, Southern University of Science and Technology Shenzhen 518000 People's Republic of China langqw@sustech.edu.cn chengq@sustech.edu.cn zhangxm@sustech.edu.cn.
Qiwei LangShenzhen Grubbs Institute, Department of Chemistry, and Medi-Pingshan, Southern University of Science and Technology Shenzhen 518000 People's Republic of China langqw@sustech.edu.cn chengq@sustech.edu.cn zhangxm@sustech.edu.cn.
Gen-Qiang ChenShenzhen Grubbs Institute, Department of Chemistry, and Medi-Pingshan, Southern University of Science and Technology Shenzhen 518000 People's Republic of China langqw@sustech.edu.cn chengq@sustech.edu.cn zhangxm@sustech.edu.cn.ORCID https://orcid.org/0000-0003-2276-6800
Xumu ZhangShenzhen Grubbs Institute, Department of Chemistry, and Medi-Pingshan, Southern University of Science and Technology Shenzhen 518000 People's Republic of China langqw@sustech.edu.cn chengq@sustech.edu.cn zhangxm@sustech.edu.cn.ORCID https://orcid.org/0000-0001-5700-0608

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The highly efficient Rh/ZhaoPhos-catalysed asymmetric hydrogenation of γ-butenolides and γ-hydroxybutenolides was successfully developed. This protocol provides an efficient and practical approach to the synthesis of various chiral γ-butyrolactones, which are synthetically valuable building blocks of diverse natural products and therapeutic substances, with excellent results (up to >99% conversion and 99% ee). Further follow-up transformations have been revealed to accomplish creative and efficient synthetic routes for several enantiomerically enriched drugs

Identifiers

PMID37181773
PMCPMC10171041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.